<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01695759</url>
  </required_header>
  <id_info>
    <org_study_id>EPOBLA1011</org_study_id>
    <secondary_id>Emenda 01 13/08/2012</secondary_id>
    <nct_id>NCT01695759</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.</brief_title>
  <official_title>Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Laboratory in Relation to Drug Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and immunogenicity of the drug test Eritromax ® - (rHuEPO
      Blau) compared to drug Eprex ® (Janssen-Cilag rHuEPO) in the treatment of patients who have
      anemia secondary to chronic kidney disease (CKD), during the correction through assessing the
      change in hemoglobin levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be assessed secondary efficacy of the drug against the test drug comparison by
      evaluating:

        -  Maintenance of hemoglobin levels (baseline vs. end of treatment) during maintenance
           phase;

        -  Dose of EPO necessary during the repair and maintenance;

        -  Need for transfusion;

        -  Safety study drugs by type, frequency and intensity of adverse events during the 12
           months of follow up.

      objectives exploratory

        -  evaluate the immunogenicity of drugs through the quantification of anti-erythropoietin
           every six months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of serum Hb (baseline vs end of treatment (EOIT)</measure>
    <time_frame>until 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Hb levels</measure>
    <time_frame>until the end of 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Epoetin alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Epoetin alpha Test will be administered subcutaneously and the initial dose of the same is 50 IU / kg. two weekly administrations will be held, totaling 100 U / kg / week. After the first 4 weeks of treatment, the dose of the drug may be modified by the Principal Investigator during the study, according to the results of laboratory tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eprex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Epoetin alphaComparator will be administered subcutaneously and the initial dose of the same is 50 IU / kg. two weekly administrations will be held, totaling 100 U / kg / week. After the first 4 weeks of treatment, the dose of the drug may be modified by the Principal Investigator during the study, according to the results of laboratory tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alpha</intervention_name>
    <description>The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.</description>
    <arm_group_label>Epoetin alpha</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eprex</intervention_name>
    <description>The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.</description>
    <arm_group_label>Eprex</arm_group_label>
    <other_name>Epoetin alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        a. Confirm voluntary participation and agree to all the purposes of the study by signing
        and dating the IC in two ways; b. Male or female, regardless of race or social class; c.
        Age between 18 and 60 years; d. Bearer dialysis-dependent CKD (hemodialysis and peritoneal
        dialysis *); and. Present clinical diagnosis of anemia, characterized in hemoglobin levels
        &lt;10g/dL before the start of the study; f. Adequate dialysis: Kt / V ≥ 1.2 for hemodialysis
        patients and ≥ 1.8 for patients on peritoneal dialysis (based on the calculation of
        Daugirdas II); g. Display adequate iron stores (TSAT&gt; 20% and serum ferritin&gt; 100ng/ml)
        prior to initiation of treatment with erythropoietin

        Exclusion Criteria:

          1. Participation in clinical trials in the 12 months preceding the survey;

          2. Patients with uncontrolled hypertension, with above average 180/100mmHg and requiring
             hospitalization in the last 6 months;

          3. Presence of other causes of anemia than CRD, such as bleeding, hemolysis, pernicious
             anemia and hemoglobinopathies;

          4. Patients who present changes or clinical abnormalities, qualified as interfering
             changes, such as severe hyperparathyroidism (iPTH&gt; 1000 pg / mL), severe congestive
             heart failure (NYHA Class IV), acute myocardial infarction within the last 3 months,
             or active neoplasia in follow-up, severe liver disease, active infection (leukocyte
             changes), history of aluminum toxicity or scheduled surgery, pregnancy or lactation;
             and. Patients who have a known hypersensitivity to any component of the formulation
             and to products derived from mammalian cells;

        f. Prior therapies with erythropoietin for less than 3 months; g. Realization transfusion
        for less than 3 months; h. Any situation at the discretion of the Principal Investigator
        interfere with study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Márcia Guidoni, manager</last_name>
    <role>Study Director</role>
    <affiliation>Blau Farmacêutica S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Frederico, physician</last_name>
    <phone>55(19) 38296160</phone>
    <phone_ext>240</phone_ext>
    <email>alexandre@lalclinica.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regiane Braga, research</last_name>
    <phone>55(11) 4615-9400</phone>
    <phone_ext>9517</phone_ext>
    <email>mguidoni@blau.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica Senhor do Bomfim Ltda</name>
      <address>
        <city>Feira de Santana</city>
        <state>Bahia</state>
        <zip>44001-584</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edson Luiz Paschoalin, physician</last_name>
      <phone>55 (75) 3211-1919</phone>
    </contact>
    <investigator>
      <last_name>Edson Luiz Paschoalin, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Scribner de Ensino, Pesquisa, Ciência e Tecnologia</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Carlos Riella, physician</last_name>
      <phone>55(41)3027-5442</phone>
      <email>mcriella@pro-renal.org.br</email>
    </contact>
    <investigator>
      <last_name>Miguel Carlos Riella, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Universitária de Caxias do Sul - Instituto de Pesquisa Clínica para Estudos Multicêntricos</name>
      <address>
        <city>Caxias do Sul</city>
        <state>Rio Grande do Sul</state>
        <zip>95070-561</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Garrafiel Bombel, physician</last_name>
      <phone>55 (54) 32187200</phone>
      <email>mgbombel@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Marcelo Garrafiel Bombel, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João Carlos Goldani, physician</last_name>
      <phone>(51) 3214-8640</phone>
      <email>ronivantxsantacasa@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>João Carlos Goldani, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domingos Otávio Lorenzoni D'Avila, physician</last_name>
      <phone>(51) 3320-3479</phone>
      <email>pesquisanefropucrs@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Domingos Otávio Lorenzoni D'Avila, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Pró-Rim</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciane Mônica Deboni, physician</last_name>
      <phone>55(47) 3434-2090</phone>
      <email>imdeboni@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Luciane Mônica Deboni, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Ensino Padre Anchieta</name>
      <address>
        <city>São Bernardo do Campo</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João Batista Douverny, physician</last_name>
      <phone>55 (11) 4930-4243</phone>
      <email>cemec.abc@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>João Batista Douverny, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMIN - Clínica De Medicina Interna E Nefrologia</name>
      <address>
        <city>São Paulo</city>
        <zip>05001-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renato Watanabe, physician</last_name>
      <phone>55(11) 3865-2634</phone>
    </contact>
    <investigator>
      <last_name>Renato Watanabe, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Oswaldo Cruz (Hospital do Rim e Hipertensão)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Eugênia Canziani, physician</last_name>
      <phone>55(11)5904-8499</phone>
      <email>dialisefor@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Maria Eugênia Canziani, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência São Paulo (Hospital Beneficência Portuguesa)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene de Lourdes Noronha, physician</last_name>
      <phone>(11) 2359-2703</phone>
      <email>irenenor@usp.br</email>
    </contact>
    <investigator>
      <last_name>Irene de Lourdes Noronha, physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2012</study_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia Secondary</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

